Condition Focus: Gout — TXNIP-ROS-NLRP3 Activation Axis
This 2023 review from Kim and colleagues in the International Journal of Molecular Sciences zooms in on a specific molecular pathway within the NLRP3 activation cascade that is particularly relevant to photobiomodulation: the TXNIP-ROS axis.
TXNIP (thioredoxin-interacting protein) is a redox sensor that normally binds to thioredoxin (TRX), an antioxidant protein. When reactive oxygen species levels rise — as they do during MSU crystal phagocytosis — TXNIP dissociates from TRX and instead binds to NLRP3, directly triggering inflammasome assembly. This means ROS does not just contribute to inflammation as a byproduct; it acts as a specific molecular signal that switches on the NLRP3 inflammasome through TXNIP.
The implication for PBM is direct. If mitochondrial ROS is the signal that triggers TXNIP-NLRP3 binding, and PBM reduces mitochondrial ROS in stressed or inflamed cells (as demonstrated by Hamblin 2018 and others), then PBM may interrupt the gout cascade at the very point where oxidative stress converts to inflammasome activation.
This is not the same as a general “antioxidant” effect. It is a specific molecular mechanism: reduced ROS → TXNIP stays bound to TRX → NLRP3 does not receive its activation signal → inflammasome does not assemble → IL-1β is not produced → flare is attenuated.
G.O.A.T. for Gout Alignment:
The G.O.A.T.’s dual wavelengths (660 nm + 850 nm) target cytochrome c oxidase in the mitochondrial electron transport chain — the primary source of the ROS that triggers TXNIP dissociation. By modulating mitochondrial ROS output, the G.O.A.T. addresses the upstream signal in the TXNIP-ROS-NLRP3 axis before the inflammasome assembles.
Link to original research here
Editor’s note: The TXNIP-ROS pathway detailed here connects to PBM’s mitochondrial effects described in Hamblin 2018, which showed PBM reduces ROS specifically in stressed cells. The broader ROS-NLRP3 activation context is reviewed in Jin et al 2023. For the hormetic (dose-dependent) nature of PBM’s ROS modulation, see PBM and Oxidative Stress 2022. The downstream IL-1β suppression that results from interrupted NLRP3 assembly is measured in Shamloo et al 2023.
Related Articles
- Mitochondrial Redox Signaling and PBM: ROS Reduction in Stressed Cells – Hamblin 2018
- Role of NLRP3 in Pathogenesis and Treatment of Gout Arthritis – Jin et al 2023
- PBM and Oxidative Stress: Mitochondrial Activity Regulation – 2022
- PBM Suppresses NLRP3 Inflammasome Outputs with Dual Wavelength – Shamloo et al 2023
- MSU Crystals Activate the NALP3 Inflammasome – Martinon et al 2006
Key Takeaways
- TXNIP-ROS axis: rising ROS causes TXNIP to dissociate from TRX and bind NLRP3, triggering assembly
- ROS is not just a byproduct — it is the specific activation signal for the gout inflammasome
- PBM reduces mitochondrial ROS in stressed cells → fewer TXNIP-NLRP3 binding events → less IL-1β
- Identifies a precise molecular target for PBM intervention in the gout cascade
Study Overview
| Study Type: | Review |
| Wavelength(s): | N/A (disease mechanism review) |
| Treatment Protocol: | N/A — maps TXNIP-ROS-NLRP3 pathway |
| Sample Size: | Review of NLRP3 activation mechanisms in gout |
| Primary Outcome: | TXNIP-ROS-NLRP3 axis identified as key inflammasome activation pathway in gout |
Full Citation
Kim YG, et al. (2023). The mechanism of NLRP3 inflammasome activation and its pathogenic implication in the pathogenesis of gout. International Journal of Molecular Sciences, 24(11), 9924. View Publication
